Prostate Cancer
Conditions
Interventions
investigational material(s)
Generic name etc : AZD3514
INN of investigational material :
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational material
Sponsors
AstraZeneca
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: - Histologically or Cytologically proven diagnosis of prostate cancer for which no standard therapy is currently considered appropriate - Documented evidence of metastatic prostate cancer - Serum testosterone concentration 50ng/dL or less - World Health Organisation (WHO) performance status 0 to 1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks
Exclusion criteria
Exclusion criteria: - History of hypersensitivity to active or inactive excipients of AZD3514 or drugs with a similar chemical structure or class to AZD3514 - Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD3514 - Inadequate bone marrow reserve or organ function - Concurrent or recent treatment with certain medications or medical procedures - Any medically important factors identified from electrocardiogram (ECG) measurements
Outcome results
None listed